爱德华生命科学(EW.US)意外下修TAVR预期后小摩与Truist大幅下调目标股价

智通财经07-26

智通财经APP获悉，7月24日(周三)爱德华生命科学公司 (EW.US) 美股盘后公布财报，该公司在业绩展望环节预计 2024 年经导管主动脉瓣置换术(TAVR)系列治疗产品的销售额增长幅度将低于此前公布的预期，随后该公司股价遭遇重挫，悲观预期令投资者们集体抛售该股，周四爱德华生命科学股价单日暴跌超31%至59.70美元。在公布最新财报后，华尔街金融巨头摩根大通以及Truist 均下调了对于该公司...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2454365916?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-26 12:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2454365916","market":"us","top_or_hot":-1,"title":"爱德华生命科学(EW.US)意外下修TAVR预期后 小摩与Truist大幅下调目标股价","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，7月24日(周三)爱德华生命科学公司 (EW.US) 美股盘后公布财报，该公司在业绩展望环节预计 2024 年经导管主动脉瓣置换术(TAVR)系列治疗产品的销售额增长幅度将低于此前公布的预期，随后该公司股价遭遇重挫，悲观预期令投资者们集体抛售该股，周四爱德华生命科学股价单日暴跌超31%至59.70美元。在公布最新财报后，华尔街金融巨头摩根大通以及Truist 均下调了对于该公司...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726121358955c2424&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>爱德华生命科学(EW.US)意外下修TAVR预期后 小摩与Truist大幅下调目标股价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n爱德华生命科学(EW.US)意外下修TAVR预期后 小摩与Truist大幅下调目标股价\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-26 12:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726121358955c2424&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，7月24日(周三)爱德华生命科学公司 (EW.US) 美股盘后公布财报，该公司在业绩展望环节预计 2024 年经导管主动脉瓣置换术(TAVR)系列治疗产品的销售额增长幅度将低于此前公布的预期，随后该公司股价遭遇重挫，悲观预期令投资者们集体抛售该股，周四爱德华生命科学股价单日暴跌超31%至59.70美元。在公布最新财报后，华尔街金融巨头摩根大通以及Truist 均下调了对于该公司...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726121358955c2424&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0256863811.USD","symbol_name":"ALLIANZ US EQUITY \"A\" INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726121358955c2424&s=b","article_id":"2454365916","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240726121358955c2424&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2454365916","pubTimestamp":1721966482,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"在公布最新财报后，华尔街金融巨头摩根大通以及Truist 均下调了对于该公司的评级以及12个月内的目标股价。爱德华生命科学第二季度总销售额仅仅同比增长8%，远未能达到市场预期，并且该公司将 TAVR 销售额展望区间从此前所预期的8% 至 10% ，意外下调至 5%至7%。爱德华生命科学是经导管主动脉瓣置换术这一创新型突破技术的先驱。Truist将爱德华生命科学的12个月内目标股价从110美元大幅下调至82美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","EW":"爱德华兹","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4082":"医疗保健设备","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4588":"碎股","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","BK4207":"综合性银行","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0106831901.USD":"贝莱德世界金融基金A2","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","BK4581":"高盛持仓","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK4504":"桥水持仓","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU0971096721.USD":"富达环球金融服务 A","LU":"陆金所","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU0882574139.USD":"富达环球消费行业基金A ACC"},"translate_title":"JPMorgan and Truist sharply lowered their price targets after Edward Life Sciences (EW.US) unexpectedly revised down TAVR expectations","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1,"LU":0.6},"content_text":"智通财经APP获悉，7月24日(周三)爱德华生命科学公司 (EW.US) 美股盘后公布财报，该公司在业绩展望环节预计 2024 年经导管主动脉瓣置换术(TAVR)系列治疗产品的销售额增长幅度将低于此前公布的预期，随后该公司股价遭遇重挫，悲观预期令投资者们集体抛售该股，周四爱德华生命科学股价单日暴跌超31%至59.70美元。在公布最新财报后，华尔街金融巨头摩根大通以及Truist 均下调了对于该公司的评级以及12个月内的目标股价。爱德华生命科学第二季度总销售额仅仅同比增长8%，远未能达到市场预期，并且该公司将 TAVR 销售额展望区间从此前所预期的8% 至 10% ，意外下调至 5%至7%。在更广泛的第三季度业绩预期方面，该公司预计第三季度总销售额区间为15.6亿美元至16.4亿美元，每股收益区间则为0.67美元至0.71美元，这两个数字都假设包括重症监护层面，基本上与市场预期相符合。公开资料显示，爱德华生命科学公司(Edwards Lifesciences Corporation)是一家全球领先的尖端医疗设备公司，总部位于美国加利福尼亚州的欧文市。该公司专注于心脏瓣膜病治疗和重症监护监测的创新产品与技术开发。爱德华生命科学是经导管主动脉瓣置换术(TAVR)这一创新型突破技术的先驱。TAVR 是一种精准的微创手术，适用于那些无法耐受传统开胸手术的重度主动脉瓣狭窄患者，通过导管将新的心脏瓣膜输送到心脏并置换受损的瓣膜，大幅减少手术风险和恢复时间。其基于TAVR治疗的主要系列产品包括SAPIEN系列的经导管心脏瓣膜。在爱德华生命科学公布业绩之后，华尔街金融巨头摩根大通 (J.P. Morgan) 对该股的评级从“跑赢大盘”下调至“中性”评级，而 Truist对于爱德华生命科学评级则从“买入”下调至“持有”。来自摩根大通的分析师Robbie Marcus在研报中表示，由于这一至关重要的业绩展望结果以及爱德华生命科学第二季度喜忧参半的整体业绩，我们认为爱德华生命科学在2025年和2026年的销售额增长率可能不会超过10%，并相应下调了我们予以的AVR预期以及公司总体的销售额以及每股收益的展望前景。摩根大通还将爱德华生命科学的12个月内目标股价从105美元大幅下调至72美元。“我们仍然看到长期性质的经导管二尖瓣和三尖瓣治疗市场的前景以及TAVR适应症扩展的乐观前景。”来自Truist的分析师Richard Newitter在最新发布的研报中指出。“但是，2024-2025年下半年的业绩加速增长路径，在我们看来出乎意料地迈入下修轨迹。”Truist将爱德华生命科学的12个月内目标股价从110美元大幅下调至82美元。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454365916"}

爱德华生命科学(EW.US)意外下修TAVR预期后 小摩与Truist大幅下调目标股价

精彩评论

爱德华生命科学(EW.US)意外下修TAVR预期后小摩与Truist大幅下调目标股价